Literature DB >> 20707756

Management of idiopathic membranous nephropathy.

Claudio Ponticelli1, Patrizia Passerini.   

Abstract

IMPORTANCE OF THE FIELD: Idiopathic membranous nephropathy (IMN) can have a variable natural course. Treatments able to induce remission can improve the long-term prognosis. However, the optimal therapy for IMN remains controversial. AREA COVERED IN THIS REVIEW: We reviewed the historical and current literature from 1979 to 2010 regarding the natural course of IMN and the possible treatments giving special emphasis to randomized controlled trials and to more recent approaches. WHAT THE READER WILL GAIN: The reader will gain a comprehensive review of the available treatments of IMN. A personal therapeutic algorithm for nephrotic patients with IMN is also provided. TAKE HOME MESSAGE: At least five different treatments showed efficacy in many (but not all) patients with IMN.

Entities:  

Mesh:

Year:  2010        PMID: 20707756     DOI: 10.1517/14656566.2010.494599

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  7 in total

Review 1.  Management of Membranous Nephropathy in Asia.

Authors:  Jing Xu; Xiaofan Hu; Jingyuan Xie; Nan Chen
Journal:  Kidney Dis (Basel)       Date:  2015-09-01

Review 2.  Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.

Authors:  Thilo C von Groote; Gabrielle Williams; Eric H Au; Yizhi Chen; Anna T Mathew; Elisabeth M Hodson; David J Tunnicliffe
Journal:  Cochrane Database Syst Rev       Date:  2021-11-15

Review 3.  Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials.

Authors:  Yizhi Chen; Arrigo Schieppati; Guangyan Cai; Xiangmei Chen; Javier Zamora; Giovanni A Giuliano; Norbert Braun; Annalisa Perna
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-28       Impact factor: 8.237

4.  The clinicopathological features of patients with membranous nephropathy.

Authors:  Hanyu Zhu; Qiuxia Han; Dong Zhang; Yong Wang; Jing Gao; Xiaoli Yang; Wenjia Geng; Xiangmei Chen
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-01-18

5.  Tetrandrine may treat membranous glomerulopathy via P13K/Akt signaling pathway regulation: therapeutic mechanism validation using Heymann nephritis rat model.

Authors:  Jiazhen Yin; Jiazhen Lin; Jin Yu; Xia Wei; Bin Zhu; Caifeng Zhu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Membranous nephropathy with repeated flares in IgG4-related disease.

Authors:  Hiroko Kanda; Junji Koya; Hiroshi Uozaki; Shoko Tateishi; Kojiro Sato; Noboru Hagino; Tetsuji Sawada; Kazuhiko Yamamoto
Journal:  Clin Kidney J       Date:  2013-02-19

7.  Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.

Authors:  WanJun Lu; ShuHao Gong; Juan Li; HongWen Luo; Ying Wang
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.